Omeros Corporation

George A Gaitanaris

Gregory A Demopulos

Patrick W Gray

Thomas L Little, Jr

Hongkui Zeng

John E Bergmann

John Hohmann

Neil S Cutshall

Linda Madisen

Roberto Ciccocioppo

Vincent A Florio

Rene Onrust

Fusheng Li

Kellie L McIlwain

Demetri Vassilatis

Maria N Pavlova

Alexander Gragerov

John G Hohmann

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

Treatment of addiction and impulse-control disorders using PDE7 inhibitors

The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.

G protein coupled receptor 85 and SREB3 knockout mice and uses thereof

A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

Use of PDE7 inhibitors for the treatment of movement disorders

Method of identifying a compound for the treatment or prevention of obesity

Disclosed herein are methods for mutagenizing a mammalian gene, the methods involving introducing into a mammalian cell a retroviral vector which includes a splice acceptor sequence, a transcription termination sequence, and retroviral packaging and integration sequences, the introducing step being carried out under conditions which allow the vector to integrate into the genome of the cell. Also disclosed are retroviral vectors for use in these methods as well as methods for the use of mutagenized cells.

Vectors and methods for the mutagenesis of mammalian genes

Growing community of inventors

Seattle, WA, United States of America

George A Gaitanaris